New 'Sandwich' strategy aims to cut leukemia relapse without donor transplant risks
NCT ID NCT06507514
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a two-step treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot have a standard donor stem cell transplant. First, patients receive the drug blinatumomab to clear any remaining cancer cells, then they undergo their own stem cell transplant (autologous HSCT). The goal is to see if this 'sandwich' approach is safe and can reduce relapse rates while avoiding the high risks of donor transplants. Only 4 participants are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab
What this could lead to
If this works, it could offer a safer consolidation option for B-ALL patients who cannot have a donor transplant, potentially reducing relapse without the high risks of donor transplants.
What could go wrong
This is a very early Phase 1 trial with only 4 participants, so results may not apply broadly. The combination approach is new and may still carry risks of relapse or side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••